Icatibant Zentiva

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with confirmed disease. GNH USA supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Zentiva acts on the bradykinin pathway to relieve acute hereditary angioedema episodes. - Hereditary angioedema type I: reduces the severity and duration of acute attacks. - Hereditary angioedema type II: provides rapid symptom relief during flare‑ups. - Hereditary angioedema with normal C1‑INH: alleviates swelling by blocking bradykinin‑mediated vascular leakage.

Icatibant Zentiva may cause a range of adverse reactions following subcutaneous injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: redness around the injection area. - Swelling: localized edema at the site. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypersensitivity: rash, itching, or swelling beyond the injection site. - Angioedema: unexpected swelling of lips, tongue, or throat. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: reduced platelet count. - Injection‑site infection: signs of local infection such as warmth, pus, or fever.

Before using Icatibant Zentiva, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: weigh potential risks and benefits with a clinician. - Renal impairment: use with caution; monitor renal function. - Concomitant ACE inhibitors or neprilysin inhibitors: monitor for enhanced bradykinin effects. - History of hypersensitivity to icatibant or excipients: avoid use. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Zentiva can interact with other medicines that influence bradykinin pathways or hemodynamics.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and risk of angioedema. - Neprilysin inhibitors: can potentiate bradykinin‑mediated effects. - Estrogen‑containing therapies: may exacerbate hereditary angioedema symptoms.

Moderate Interactions (Monitor Closely): - NSAIDs: watch for additive swelling or pain at injection sites. - Diuretics: monitor blood pressure and electrolyte balance during therapy.